Brief Insight About Management Of Meningioma

Abstract

Background: Meningiomas account for approximately 1/3 of primary intracranial tumours in adults, with an age-adjusted incidence rate of approximately 7 per 100,000 person-years. meningiomas comprises 37.6% of all primary CNS tumors and 53.3% of all benign CNS tumors. Meningiomas arise from meningothelial (arachnoid) cells (MECs). These cells are a cellular component of the pia mater, arachnoid mater, and the trabeculae and septae of the subarachnoidal space. Arachnoid cap cells make up the outer layer of the arachnoid mater and arachnoid villi and with cytological similarities to meningiomas cells, it is likely their cell of origin. Meningiomas are most commonly seen in the following areas: convexity (lateral hemisphere) (20–37%); parasagittal (medial area of hemispheres) (13–22%) (includes falcine meningiomas (5%)); spinal (7–12%); skull base (43–51%); frontobasal (10–20%); sphenoid and middle cranial fossa (9–36%); posterior fossa (6–15%); tentorium cerebelli (2–4%); cerebellar convexity (5%); cerebellopontine angle (2–11%); foramen magnum (3%); and petroclival (<1–9%); intraventricular (1–5%); orbital (<1–2%); and ectopic locations (<1%). The presentation of meningiomas are often non-specific, but location and compression of adjacent brain and vascular structures can lead to focal neurologic deficits (including cranial nerve deficits) [54]. Symptoms that are commonly seen are as follows: headache (33.3–36.7%), focal cranial nerve deficit (28.8–31.3%), seizure (16.9–24.6%), cognitive change (14.4%), weakness (11.1%), vertigo/dizziness (9.8%), ataxia/gait change (6.3%), pain/sensory change (5.6%), proptosis (2.1%), syncope (1.0%), and asymptomatic (9.4%). management for meningiomas is highly individualized and includes a combination of observation, surgical resection, radiotherapy, and rarely chemotherapy. The potential consequences of different treatments can vary greatly. Through recent advances in neurosurgery, neuroimaging, and neuroanesthesia, patients are experiencing better long-term outcomes, retreatment free survival, and overall survival. Surgical resection is the primary choice for symptomatic, observation failure meningiomas, or large tumors that are anticipated to causes symptoms soon. gross total resection (GTR) can cure the majority (70–80%) of patients. Radiation therapy (RT) has become a first-line treatment for unresectable meningiomas, such as certain skull base meningiomas that have encased neurovascular structures. Patients who develop recurrent or progressive meningiomas that no longer respond to surgery or radiotherapy are treated with salvage systemic therapy. The National Comprehensive Cancer Network (NCCN) recommends the use of α-IFN, somatostatin receptor agonists, and vascular endothelial growth factor (VEGF) inhibitors for the treatment of meningioma.